Abstract

Objective To investigate the changes of plasma lipoprotein-associated phospholipase A2 (LP-PLA2) levels in patients with nonvalvular atrial fibrillation (NVAF) and the effects of statins.Methods The changes of plasma LP-PLA2 levels were determined in 169 cases of NVAF who didn' t recieve any antithrombotic therapy and 124 cases controls,and the difference between them was compared.One hundred and sixty-nine NVAF patients were randomly divided into three groups:52 cases in NVAF control group,61 cases in aspirin group and 56 cases in aspirin combined with atorvastatin group.Patients in NVAF control group didn't recieve any treatment,the aspirin group was given aspirin 100 mg/d,and the aspirin combined with atorvastatin group was given aspirin 100 mg/d + atorvastatin 10 mg/d.The content of plasma LP-PLA2 levels were determined by ELISA among the three groups before treatment and 3 months,1 year after treatment.Results LP-PLA2 levels were significantly increased in NVAF group [(187 ± 14) ng/L],compared with controls [(147 ± 14) ng/L] (P ＜ 0.01).Before treatnent,3 months and 1 year after treatment,the content of plasma LP-PLA2 levels were (187 ±14),(190 ± 16),(196 ± 16) ng/L in NVAF group respectively,the difference had no statistical significance(P ＞0.05).The content of plasma LP-PLA2 levels were (191 ± 15),(179 ± 12),(165 ±15)ng/L in aspirin group respectively,and the LP-PLA2 levels were significant decreased after treatment,compared with brfore treatment(P ＜0.01) ; The content of plasma LP-PLA2 levels were (193 ±16),(152 ± 14),(141 ± 12) ng/L in aspirin combined with atorvastatin group respectively,the LP-PLA2 levels were significant decreased after treatment,compared with before treatment(P ＜ 0.01),and it was significantly decreased than that in aspirin group(P ＜ 0.01).Conclusions The plasma LP-PLA2 levels were significantly elevated in NVAF.The content of plasma LP-PLA2 levels were significant decreased by aspirin combined with atorvastatin,statins had neuroprotective effects and may be as a new anti-inflammation agent used in antithrombotic therapy of NVAF patients. Key words: Atrial fibrillation; Lipoprotein-associated phospholipase A2 ; Ischemic stroke ; Atorvastatin

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.